290 related articles for article (PubMed ID: 30528803)
1. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
2. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Fazal M; Prentice DA; Kho LK; Fysh E
Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(4):263b. PubMed ID: 29176295
[No Abstract] [Full Text] [Related]
4. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
6. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
[No Abstract] [Full Text] [Related]
7. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Emile J; Cauquil C; Carpentier D; Routier E; Robert C
Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
[No Abstract] [Full Text] [Related]
8. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
9. Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
Tadokoro T; Keshino E; Makiyama A; Sasaguri T; Ohshima K; Katano H; Mohri M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27650418
[No Abstract] [Full Text] [Related]
10. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
11. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA
Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-associated ocular myasthenia gravis.
Liu Q; Ayyappan S; Broad A; Narita A
Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
[No Abstract] [Full Text] [Related]
15. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
Esfahani K; Buhlaiga N; Thébault P; Lapointe R; Johnson NA; Miller WH
N Engl J Med; 2019 Jun; 380(24):2375-2376. PubMed ID: 31189042
[No Abstract] [Full Text] [Related]
17. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
18. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
19. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
20. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
